NIDDM is a heterogeneous disease and subgroups of NIDDM include MODY (
Maturity Onset Diabetes of the Young), Malnutrition-related diabetes (
MRDM) and Fibrocalculus pancreatic diabetes (FCPD). Endocrine cell pop
ulation is relatively unchanged in NIDDM: B-cells are reduced by up to
30% and A-cells increased by 10%. Islet amyloid is found in 96% of su
bjects occupying up to 80% of the islet associated with a reduction in
B-cells. Amyloid formation is unlikely to cause diabetes but progress
ive accumulation increases the severity of the disease. Islet amyloid
is formed from the islet amyloid polypeptide (LAPP), a normal constitu
ent of B-cells, co-secreted with insulin. The causal factors for IAPP
fibrillogenesis are unknown but abnormal synthesis or overproduction c
ould be involved: stimulation of B-cell secretion in NIDDM by obesity,
hyperglycaemia or suphonylurea therapy may promote amyloidosis and fu
rther aggravate islet pathology. A mutation of the glucokinase gene in
MODY leads to diminished B-cell secretion but not amyloid formation.
Diabetes and mutations of mitochondrial DNA is associated with poorly
developed islet structure. Exocrine pancreatic size is reduced and the
re is evidence of sub-clinical chronic pancreatitis in NIDDM. In MRDM
and FCPD, chronic pancreatitis and exocrine necrosis is associated wit
h reduced insulin secretion. Unlike cystic fibrosis where islet amyloi
d is present in diabetic individuals, amyloid is absent from subjects
with FCPD. Pathological changes in the exocrine and endocrine pancreas
in NIDDM results from and contributes to the pathophysiology of insul
in secretion in NIDDM.